News (93)

Transcript : Amylyx Pharmaceuticals, Inc. - Special Call
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome BU
Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO, ALBRIOZA from the Market, Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy AQ
Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy BU
Transcript : Amylyx Pharmaceuticals, Inc. - Special Call
Transcript : Amylyx Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 22, 2024
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results BU
Amylyx Pharmaceuticals Announces Completion of Enrollment in HELIOS, a Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome BU
Amylyx Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4) AQ
Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BU
Transcript : Amylyx Pharmaceuticals, Inc. Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-28-2023 02:10 PM
Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer BU
Amylyx Pharmaceuticals Appoints Camille L. Bedrosian as Chief Medical Officer CI
Transcript : Ultragenyx Pharmaceutical Inc. - Analyst/Investor Day
RHYTHM PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K) AQ
ULTRAGENYX PHARMACEUTICAL INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) AQ
ULTRAGENYX PHARMACEUTICAL INC. : Change in Directors or Principal Officers (form 8-K) AQ
Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President GL
Ultragenyx Pharmaceutical Inc. Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President CI
Transcript : Ultragenyx Pharmaceutical Inc., Q4 2022 Earnings Call, Feb 16, 2023
Transcript : Ultragenyx Pharmaceutical Inc., Q3 2022 Earnings Call, Nov 02, 2022
ULTRAGENYX PHARMACEUTICAL INC. : Change in Directors or Principal Officers (form 8-K) AQ
Transcript : Ultragenyx Pharmaceutical Inc., Q2 2022 Earnings Call, Jul 28, 2022
Transcript : Ultragenyx Pharmaceutical Inc. - Special Call
Transcript : Rhythm Pharmaceuticals, Inc. - Shareholder/Analyst Call
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-2022 02:40 PM
Transcript : Ultragenyx Pharmaceutical Inc., Q1 2022 Earnings Call, May 05, 2022
Ultragenyx to Participate at BofA Securities 2022 Healthcare Conference GL
Ultragenyx to Participate at BofA Securities 2022 Healthcare Conference GL
Mereo BioPharma : Our Partner Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta PU
Mereo BioPharma : Our Partners Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta PU
Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta AQ
Transcript : Ultragenyx Pharmaceutical Inc., Q4 2021 Earnings Call, Feb 10, 2022
Ultragenyx Announces First Patient Dosed in Phase 1/2 Clinical Study of UX053, an mRNA Therapy for the Treatment of Glycogen Storage Disease Type III AQ
Transcript : Ultragenyx Pharmaceutical Inc., Q3 2021 Earnings Call, Nov 02, 2021
Transcript : Ultragenyx Pharmaceutical Inc., Q2 2021 Earnings Call, Aug 02, 2021
CRINETICS PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K) AQ
Transcript : Rhythm Pharmaceuticals, Inc. - Shareholder/Analyst Call
Transcript : Ultragenyx Pharmaceutical Inc. Presents at BofA Securities 2021 Virtual Health Care Conference, May-12-2021 03:30 PM
Ultragenyx to Present at Bank of America Securities Healthcare Conference GL
Transcript : Ultragenyx Pharmaceutical Inc., Q1 2021 Earnings Call, May 04, 2021
Crinetics Pharmaceuticals : Announces 2021 Clinical Plans and Reports Fourth Quarter and Full Year 2020 Financial Results AQ
Ultragenyx Pharmaceutical : Announces FDA Clearance of Investigational New Drug (IND) Application for UX053, an mRNA for the Treatment of Glycogen Storage Disease Type III AQ
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results GL
Ultragenyx Pharmaceutical : Announces Approval of Dojolvi in Canada for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and Children AQ
123NextSee all

Companies (1)

CAMIL ALIMENTOS S.A. 555 M $
Logo Camil Alimentos S.A.

Camil Alimentos SA is a Brazil-based company primarily engaged in the food processing sector. The Company focuses on the manufacture and commercialization of rice, rice crackers, beans, peas, chickpeas and lentil seeds, soybean-based meals, popcorn, sugar ...


Insiders

Picture Camille Bedrosian
Camille Bedrosian

Dr. Camille L. Bedrosian, MD, is an Independent Director at Rhythm Pharmaceuticals, Inc., an Independent Director at Crinetics Pharmaceuticals, Inc., a Chief Medical Officer & Executive Vice President at Ultragenyx Pharmaceutical, Inc., a Member at American Society of Clinical Oncology, a Member at American Society of Hematology and a Member at American Society of Nephrology. She is on the Board of Directors at Rhythm Pharmaceuticals, Inc. and Crinetics Pharmaceuticals, Inc. Dr. Bedrosian was previously employed as a Chief Medical Officer & Senior Vice President by Alexion Pharmaceuticals, Inc., a Chief Medical Officer & Vice President by ARIAD Pharmaceuticals, Inc., a Senior Director-Oncology & Hematology by Genetics Institute, Inc., a Member by American Association for Cancer Research, a Member by American Association for the Advancement of Science, a Member by Duke Comprehensive Cancer Center, and an Assistant Professor by Duke University Medical Center. She received her undergraduate degree from Harvard University, a graduate degree from Massachusetts Institute of Technology and a doctorate degree from Harvard Medical School.





Picture John C. Bedrosian
John C. Bedrosian

John C.
Bedrosian
is currently a Director at The International Dairy Foods Association, All Star Dairy Foods, Inc., and Dairy Institute of California.
He was formerly a Director at The American Institute of Baking and Vice President-Manufacturing at UNFI Grocers Distribution, Inc. Bedrosian obtained an undergraduate degree from The California State University.



Picture John C. Bedrosian
John C. Bedrosian

John C.
Bedrosian
is the founder of AutoWeb, Inc. which was founded in 1995.
He also worked as a Director at Oaks Christian School.




No results for this search